Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Aptevo Therapeutics Inc

APVO

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $0.46 – $0.584
Volume 97,807
Market cap $1M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.16M
Price / earnings
—
Price / book
0.19×
Price / sales
—
EV / sales
—
EV / EBITDA
0.32×

Profitability

Earnings per share
-$13.24
Return on assets
-192.71%
Return on equity
-463.15%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
2.08×
Quick ratio
2.08×
Cash ratio
1.89×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$25.34M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for APVO, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$2.75M$2.91M$2.46M$3.57M$2.9M$2.85M$2.5M$2.11M
Research and development$3.7M$3.92M$3.54M$4.04M$3.33M$3.63M$3.88M$3.1M
Total operating expenses$6.44M$6.84M$6M$7.61M$6.23M$6.48M$6.38M$5.21M
Operating income-$6.44M-$6.84M-$6M-$7.61M-$6.23M-$6.48M-$6.38M-$5.21M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$6.36M-$6.7M-$5.81M-$7.55M-$6.2M-$6.41M-$6.31M-$5.1M
Income taxes$0$0$0$0$0$0$0$0
Net income-$6.36M-$6.7M-$5.81M-$7.55M-$6.2M-$6.41M-$6.31M-$5.1M
Net income attributable to common shareholders-$6.36M-$6.7M-$5.9M-$9.03M-$6.2M-$6.41M-$6.31M-$5.1M
EBITDA-$6.41M-$6.8M-$5.92M-$7.56M-$6.18M-$6.42M-$6.31M-$5.13M
Basic earnings per share-$5.31-$6.41-$5.94-$40.14-$151.29-$1,581.81-$3,219.86-$6,441.48
Diluted earnings per share-$5.31-$6.41-$5.94-$40.14-$151.29-$1,581.81-$3,219.86-$6,441.48

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
The Motley Fool

Aptevo Reports 85% Remission in Q2

Aptevo Therapeutics reported a net loss of $8.40 per share in Q2 2025, significantly better than analyst estimates. The company's lead bispecific antibody, mipletamig, showed promising 85% remission rates in acute myeloid leukemia trials, and raised $15.9 million in equity to extend its cash runway.

Zacks Investment Research

Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These are Vita Coco Company (COCO), AMC Entertainment (AMC), Hyperfine (HYPR), Aptevo Therapeutics (APVO) and CLEAR Secure (YOU).

Zacks Investment Research

Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Groupon (GRPN), Aptevo Therapeutics (APVO), NewJersey Resources (NJR), American Water Works (AWK) and Frontdoor (FTDR).

Zacks Investment Research

Aptevo (APVO) Stock Plummets 79% in a Week: Here's Why

Aptevo (APVO) plunges after it issues secondary shares, which are not only issued at a significant discount but also substantially dilute the existing shareholder base.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Dec 30, 20251-for-18reverse split
May 27, 20251-for-20reverse split
Dec 4, 20241-for-37reverse split
Mar 6, 20241-for-44reverse split
Mar 27, 20201-for-14reverse split